Calidi Biotherapeutics Inc. Pioneers Precision Genetic Medicine for Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is making strides in the fight against cancer with its precision genetic medicine platform, a development that could not come at a more critical time. With global cancer diagnoses expected to soar to 35 million annually by 2050, the need for innovative treatments is more pressing than ever. Calidi's platform stands out by employing engineered viruses to target both primary and metastatic cancer tumors, offering a novel approach that could significantly alter the oncology landscape.

The company's technology is designed to deliver potent genetic therapies directly to cancer sites, a method that promises to enhance treatment efficacy while improving patient safety. This is particularly relevant for high-grade gliomas and solid tumors, where current treatment options are often limited. Calidi's clinical-stage, off-the-shelf, universal cell-based delivery platforms are engineered to protect, amplify, and potentiate oncolytic viruses, potentially unlocking new possibilities in cancer therapy.

For those interested in learning more about Calidi Biotherapeutics and its innovative work, visit https://www.calidibio.com. Additional updates on CLDI can be found in the company's newsroom at https://ibn.fm/CLDI.